<DOC>
	<DOCNO>NCT01373333</DOCNO>
	<brief_summary>Compassionate use orphan drug 3,4-Diaminopyridine ( DAP ) Treatment Lambert Eaton Myasthenic Syndrome ( LEMS ) . 3,4-DAP used decrease muscle weakness associate LEMS hopefully decrease need prednisone therapy previously require control symptom . How long patient take 3,4 DAP depend upon he/she see benefit medication experience side effect prevent continuation study .</brief_summary>
	<brief_title>Use Of 3,4-Diaminopyridine ( 3,4-DAP ) In The Treatment Of Lambert Eaton Myasthenic Syndrome</brief_title>
	<detailed_description>3,4-diaminopyridine ( 3,4-DAP ) decrease symptoms weakness patient LEMS , therefore use decrease amount immune modulation therapy need provide equivalent degree disease control .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>1 . Clinical diagnosis LEMS without follow : evidence underlying malignancy , presence P/Q Ntype calcium channel antibody , electrodiagnostic evidence presynaptic defect neuromuscular junction transmission.None laboratory finding require inclusion study . 2 . P/Q N type calcium channel antibody measure blood routine laboratory test course initial diagnosis , 1020 % patient LEMS elevate level antibody . 1 . Hypersensitivity component medication . 2 . History past current seizure . 3 . History asthma . 4 . Evidence prolong QT syndrome . There absolute upper limit normal QTc interval . 5 . Family history prolonged QTc syndrome , history unexplained syncope , seizures cardiac arrest .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>